Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elena Elli

Showing results (1-10 of 18) with videos related to

Pageof 2
Sort By:
Mediterranean Journal of Hematology and Infectious Diseases|May 3, 2012
A Case of Atypical Delayed and Prolonged Hematologic Toxicity With Azacitidine in Chronic Myelomonocytic Leukemia (CMML) and Review of LiteratureElena Elli, Caterina Cecchetti, Angelo Belotti, et al.
American Journal of Hematology|December 23, 2011
Circulating endothelial cells and endothelial activation in essential thrombocythemia: results from CD146+ immunomagnetic enrichment--flow cytometry and soluble E-selectin detectionAngelo Belotti, Elena Elli, Tiziana Speranza, et al.
Blood Reviews|April 28, 2018
Iron toxicity - Its effect on the bone marrowAlessandro Isidori, Lorenza Borin, Elena Elli, et al.
Mediterranean Journal of Hematology and Infectious Diseases|June 16, 2015
Good Outcome for Very High Risk Adult B-cell Acute Lymphoblastic Leukaemia Carrying Genetic Abnormalities t(4;11)(q21;q23) or t(9;22)(q34;q11), if Promptly Submitted to Allogeneic Transplantation, after Obtaining a Good Molecular RemissionMatteo Parma, Clara Viganò, Monica Fumagalli, et al.
Transfusion|July 1, 2005
Peripheral blood progenitor cell collection in chronic myeloid leukemia patients with complete cytogenetic response after treatment with imatinib mesylatePaolo Perseghin, Carlo Gambacorti-Passerini, Lucia Tornaghi, et al.
American Journal of Hematology|November 23, 2013
Pregnancy complications predict thrombotic events in young women with essential thrombocythemiaMaria Luigia Randi, Irene Bertozzi, Elisa Rumi, et al.
Hematological Oncology|May 4, 2019
Treatment of Philadelphia-negative myeloproliferative neoplasms in accelerated/blastic phase with azacytidine. Clinical results and identification of prognostic factorsAlessandro Andriani, Elena Elli, Giulio Trapè, et al.
British Journal of Haematology|August 19, 2014
A lower intensity of treatment may underlie the increased risk of thrombosis in young patients with masked polycythaemia veraFederico Lussana, Alessandra Carobbio, Maria L Randi, et al.
American Journal of Hematology|January 7, 2010
Leukocytosis is a risk factor for recurrent arterial thrombosis in young patients with polycythemia vera and essential thrombocythemiaValerio De Stefano, Tommaso Za, Elena Rossi, et al.
Annals of Hematology|July 8, 2009
Increased risk of recurrent thrombosis in patients with essential thrombocythemia carrying the homozygous JAK2 V617F mutationValerio De Stefano, Tommaso Za, Elena Rossi, et al.
Pageof 2

Showing results (1-10 of 18) with videos related to

Sort By:
Pageof 2
Mediterranean Journal of Hematology and Infectious Diseases|May 3, 2012
A Case of Atypical Delayed and Prolonged Hematologic Toxicity With Azacitidine in Chronic Myelomonocytic Leukemia (CMML) and Review of LiteratureElena Elli, Caterina Cecchetti, Angelo Belotti, et al.
American Journal of Hematology|December 23, 2011
Circulating endothelial cells and endothelial activation in essential thrombocythemia: results from CD146+ immunomagnetic enrichment--flow cytometry and soluble E-selectin detectionAngelo Belotti, Elena Elli, Tiziana Speranza, et al.
Blood Reviews|April 28, 2018
Iron toxicity - Its effect on the bone marrowAlessandro Isidori, Lorenza Borin, Elena Elli, et al.
Mediterranean Journal of Hematology and Infectious Diseases|June 16, 2015
Good Outcome for Very High Risk Adult B-cell Acute Lymphoblastic Leukaemia Carrying Genetic Abnormalities t(4;11)(q21;q23) or t(9;22)(q34;q11), if Promptly Submitted to Allogeneic Transplantation, after Obtaining a Good Molecular RemissionMatteo Parma, Clara Viganò, Monica Fumagalli, et al.
Transfusion|July 1, 2005
Peripheral blood progenitor cell collection in chronic myeloid leukemia patients with complete cytogenetic response after treatment with imatinib mesylatePaolo Perseghin, Carlo Gambacorti-Passerini, Lucia Tornaghi, et al.
American Journal of Hematology|November 23, 2013
Pregnancy complications predict thrombotic events in young women with essential thrombocythemiaMaria Luigia Randi, Irene Bertozzi, Elisa Rumi, et al.
Hematological Oncology|May 4, 2019
Treatment of Philadelphia-negative myeloproliferative neoplasms in accelerated/blastic phase with azacytidine. Clinical results and identification of prognostic factorsAlessandro Andriani, Elena Elli, Giulio Trapè, et al.
British Journal of Haematology|August 19, 2014
A lower intensity of treatment may underlie the increased risk of thrombosis in young patients with masked polycythaemia veraFederico Lussana, Alessandra Carobbio, Maria L Randi, et al.
American Journal of Hematology|January 7, 2010
Leukocytosis is a risk factor for recurrent arterial thrombosis in young patients with polycythemia vera and essential thrombocythemiaValerio De Stefano, Tommaso Za, Elena Rossi, et al.
Annals of Hematology|July 8, 2009
Increased risk of recurrent thrombosis in patients with essential thrombocythemia carrying the homozygous JAK2 V617F mutationValerio De Stefano, Tommaso Za, Elena Rossi, et al.
Pageof 2